To study the influence of donor's ABCB1、CYP3A4、CYP3A5、POR genetic polymorphism on tacrolimus blood concentration in liver transplant recipients.
This study will start with a retrospective data analysis. The investigators will use the electronic databases of National Taiwan University Hospital to identify patients who underwent liver transplantation, received tacrolimus and were still followed up at the outpatient clinic. Inclusion and exclusion criteria will be applied to screen appropriate participants, and find their donors. And analyze the effect of genetic polymorphism (ABCB1、CYP3A4、CYP3A5、POR) of donors, including other factors of recipients, on the dose normalized trough concentration of tacrolimus.
Study Type
OBSERVATIONAL
Enrollment
96
National Taiwan University Hospital
Taipei, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Dose normalized trough concentration of tacrolimus in liver transplant patients within the first 6 months post-transplantation
Analyse the effect of the donor's genetic polymorphism to dose normalized trough concentration of tacrolimus in liver transplant patients. Trough level of tacrolimus was adjusted by liver recipient's body weight.
Time frame: Within the first 6 months post-transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.